Compass Therapeutics (CMPX) Profit After Tax (2023 - 2025)
Historic Profit After Tax for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$14.3 million.
- Compass Therapeutics' Profit After Tax fell 3604.62% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.8 million, marking a year-over-year decrease of 3778.76%. This contributed to the annual value of -$49.4 million for FY2024, which is 1619.29% down from last year.
- As of Q3 2025, Compass Therapeutics' Profit After Tax stood at -$14.3 million, which was down 3604.62% from -$19.9 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Profit After Tax high stood at -$7.8 million for Q1 2023, and its period low was -$19.9 million during Q2 2025.
- For the 3-year period, Compass Therapeutics' Profit After Tax averaged around -$13.0 million, with its median value being -$13.1 million (2024).
- Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 518.87% in 2024, then tumbled by 5419.49% in 2025.
- Over the past 3 years, Compass Therapeutics' Profit After Tax (Quarter) stood at -$13.4 million in 2023, then fell by 12.06% to -$15.0 million in 2024, then increased by 5.15% to -$14.3 million in 2025.
- Its last three reported values are -$14.3 million in Q3 2025, -$19.9 million for Q2 2025, and -$16.6 million during Q1 2025.